William G. Wierda, MD, PhD | Authors


Reviewing Key Points from the Phase III MURANO Trial in CLL

May 11, 2019

William G. Wierda, MD, PhD, discusses the take home message from the phase III MURANO trial that identified venetoclax plus rituximab as a new treatment option for patients with relapsed/refractory chronic lymphocytic leukemia.

Sequencing Agents in CLL

October 25, 2017

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing agents in chronic lymphocytic leukemia (CLL).